Immunopathogenesis of Multiple Sclerosis (MS)
of neurological impairment or symptoms that involve multiple regions of CNS damage. Early MS may spontaneously resolve Multiple sclerosis (MS) is a chronic disease of the CNS that is partially or completely, but often the disease course becomes characterized by progressive loss of motor and sensory nerve chronic and unremitting, leading to loss of ambulation and dexterifunction and immune-mediated inflammation and demyelination.
[1] Clinically, most MS patients experience multiple episodes ty, and cognitive and psychological deficits.
The most important unresolved issue in MS today is the lack of many EAE studies. Moreover, it now appears that within each MS a clear understanding of what causes MS. Although Jean-Martin patient, active lesions have one of four distinct profiles. [8] Most Charcot described MS more than 140 years ago, [2] its etiology lesions apparently result from immune-mediated myelin destrucremains a mystery. Consequently, insights into its causation would tion, as expected, whereas others may involve an oligodendrocyte represent a major advance in the field. Without knowledge of its dystrophy, perhaps induced by toxins or infection and without a cause, there can be no real cure for MS -only treatments that may strong autoimmune component. As mentioned earlier, it was only diminish its progression. The current major research effort in MS recently appreciated that MS involves progressive neuronal loss is directed at such disease-modifying strategies. Taken together, and a reduction in the total brain volume.
[3] Thus, one cannot rule the available therapies for MS have certainly had some beneficial out the possibility that MS is primarily a neurodegenerative diseffect on lesion formation and relapse rates, but do not appear to ease that may or may not include a superimposed autoimmuneimpede disease progression significantly. mediated inflammatory process directed at myelin or other CNS antigens. Viewed from this perspective, loss of neurons could be From an imaging standpoint, MS is characterized by focal MRI the force driving disease progression, leading to associated myelin changes suggesting local inflammation, which can occur throughdamage. Whether neuronal damage might emanate from neurotroout the CNS. Histologically, perivenular inflammatory lesions phic agents such as viruses or non-lethal prions is debatable, but it involving infiltrating mononuclear cells are evident in the earlier is now clear from the EAE models that inflammation itself (in the phases of the disease, and these regions may coalesce into scariabsence of such neurotrophic agents) can result in nerve death fied macroscopic plaques concomitant with CNS tissue damage similar to that observed in MS. [9] This is a key observation that and disease progression. Demyelination is a hallmark feature of provides the rationale to continue the quest for effective anti-MS, clearly involving damage or loss of oligodendrocytes and inflammatory therapies for MS, including immunomodulators. disruption of nerve conduction and signal integration through affected regions. It is now recognized that the MS disease process results in damage and eventual death of neurons themselves.
[3]
MS May Involve Myelin-Reactive T Cells
Early effects on nerve cells may be reversible, and functional damage may initiate compensatory conduction pathways. HowIt is probable that T h1 cells specific for encephalitogenic myeever, as the insult continues and nerve cells die, lost function lin antigens, including myelin basic protein (MBP), proteolipid cannot be restored, resulting in disease progression. [4] protein (PLP) and myelin oligodendrocyte glycoprotein (MOG), In the absence of known agents or factors known to cause MS, contribute to the pathogenesis of MS. [10] Collectively, data supthe field has gravitated towards testing the assumption that MS is porting a role for myelin antigens in the pathogenesis of MS caused or propagated by an autoimmune process involving ininclude: (i) an increased frequency of MBP-, PLP-, MOG-, and α-flammatory T cells directed at myelin self antigens. A working B-crystallin-specific T cells in the blood or cerebrospinal fluid hypothesis, known as molecular mimicry, is that cross-reactive (CSF) of MS patients, compared with control individuals; [11] [12] [13] [14] [15] [16] [17] [18] antigens expressed by an as-yet-unknown virus or another micro-(ii) an increased state of activation of MBP-and PLP-specific or organism activate the myelin-specific T cells that initiate an enother oligoclonal T cells in the blood and CSF of MS pacephalitogenic cascade, similar to inducible or spontaneous forms tients [3, 13, [19] [20] [21] [22] [23] (and Abulafia-Lapid R et al., unpublished data); of experimental autoimmune encephalomyelitis (EAE). [5, 6] An (iii) sporadic increases in the frequency of MBP-specific T cells alternative and potentially overlapping immune hypothesis is that that correlate with disease activity in MS patients; [24, 25] (iv) poss-MS results when naturally occurring myelin-specific T cells exible therapeutic efficacy of intervention strategies directed at pand to a critical pathogenic frequency due to diminished im-MBP-specific T cells; [25] [26] [27] (v) exacerbation of disease activity in munoregulatory mechanisms (i.e. T helper-2 [Th2], Th3, T regula-MS patients treated with an altered peptide ligand for MBP; [28] and tory [Treg] type 1, CD4+CD25+ Foxp3+ Treg, or CD8+ T cells). [7] (vi) demonstrated encephalitogenicity of MBP, PLP, and MOG Although the autoimmune hypothesis has many attractive feaepitopes in EAE that are also immunogenic in MS patients. tures, it does not fully explain the pathophysiology of MS. In
Because of the extensive literature available, and the recently particular, the frequency of T cells responding to myelin antigens reported ability of MBP-specific clones to be stimulated by a in MS patients is approximately 10-fold lower than T-cell frequenvariety of microbial and self antigens, [29] MBP must be viewed as a cies responding to recall antigens such as Herpes simplex virus or useful prototypic myelin target antigen in MS, but it is now widely tetanus toxoid, and are lower than would be expected based on recognized that PLP, MOG, or other as yet unrecognized myelin antigens may also participate as encephalitogens. In MS patients mined. The exclusion of immune cells migrating into the CNS in of northern European descent, there is a disease association MS patients treated with a combination of natalizumab and with the human leukocyte antigens (HLA)-DR2, an allele Avonex ® 1 (interferon-β-1a) resulted in progressive multifocal (DRA:DRB1*1501) of major histocompatibility complex (MHC) leukoencephalitis (PML) in ≈1/1000 patients, thus limiting its class II, and HLA-DQw6, with different class II associations applicability to a subset of patients. This being said, the increased (i.e. DR3, DR4, and DR6) in other populations. [30] [31] [32] [33] Although the efficacy shown by natalizumab is yet another indication that role of the MHC in the MS disease process has not been fully blockade of immune-mediated inflammation is likely to be a defined, it is well accepted that class II molecules, particularly fruitful avenue for future drug development in MS. Notably, HLA-DR2, [34] can present encephalitogenic myelin epitopes to success in early phase MS trials with the drug fingolimod potentially pathogenic T cells. These findings provide the ratio-(FTY720), a sphingosine-1-phosphate receptor modulator, may be nale for using T-cell vaccination (TCV) to target the T-cell recepdue to its relatively unique ability to inhibit the number of circulattors (TCRs) of myelin antigen-specific T cells in MS, which is the ing CD4+ T cells and B cells that escape from the spleen and other subject of this review. Alternatively, disease-associated MHC peripheral lymphoid organs. [38] class II molecules could be inefficient at presenting regulatory There now appear to be a number of different approaches in peptides to inhibitory T cells that normally limit the activation of development that target T-cell activation through the TCR. These autoreactive T cells.
have been recently reviewed, [39] and include tolerance induced with soluble antigen, peptide/MHC complexes, altered peptide 3. Therapeutic Approaches for MS ligands, antigen-based DNA vaccines, monoclonal antibodies to co-stimulatory molecules and inflammatory cytokines, TCR pepIn addition to the anti-inflammatory drugs such as corticostertide therapy, and the approach that is the focus of this reviewoids that may temporarily relieve acute symptoms of MS, treat-TCV to attenuated myelin-reactive T cells. Collectively, these ment options for MS are currently limited to three different forms approaches hold the promise of selective inhibition of inflammaof interferon-β, glatiramer acetate, [35] mitoxantrone, and nataltion initiated by key T-cell specificities without broad-based imizumab, a humanized monoclonal antibody to α4 integrin. The munosuppressive adverse effects. interferon therapies have only moderate anti-inflammatory properties, but have the added feature of inhibiting viral infections, which 4. Rationale for T-Cell Vaccination (TCV) conceivably could play a role in MS. However, in the long term, the interferons may have only a limited impact on nerve damage Like the classic notion of inducing immune recognition of and disease progression. Glatiramer acetate is a random oligopepattenuated pathogenic organisms (i.e. smallpox), TCV involves tide copolymer that can induce a set of peptide-reactive T cells vaccination with attenuated T cells that are specific for myelin with an anti-inflammatory cytokine profile, and the moderate peptides and, as such, would potentially be encephalitogenic in success of this drug may derive from a bystander suppression humans without the attenuation step. Although such cells bear self mechanism mediated by secreted cytokines, as well as neuroproproteins, it is now well accepted that tolerance to self can be tective and neurogenic activity, according to recent claims. Mitobroken relatively easily after exposure of the immune system to xantrone has strong antiproliferative activity and may mediate its rare or altered peptide sequences. In many cases, self proteins are moderate effect in advanced MS patients by inhibiting broadalready being recognized by immunocytes or antibodies, but with spectrum T-cell and B-cell expansion.
a non-inflammatory outcome. Thus, injection of attenuated myeThe newest drug available to MS patients who have not relin-specific T cells might be expected to induce processing of self sponded to other therapies is natalizumab. [36, 37] This drug blocks components by macrophages, dendritic cells, and B cells, potenthe attachment of peripheral immune cells to the CNS vascular tially leading to a wide variety of T-cell specificities that might endothelium, and thereby greatly inhibits the entry of myelinregulate the targeted T cells. This concept was introduced by specific T cells and recruited inflammatory cells from the periCohen and colleagues [40] in 1981, who demonstrated protection phery into the CNS. Natalizumab has more potent therapeutic and therapy of EAE using activated and irradiated MBP-specific activity than the other available therapies, especially in preventing T-cell clones. The responsive regulatory cells included those direlapses, but its long-term impact on MS remains to be deterrected at the unique TCR on the targeted pathogenic T cells (anti-idiotypic) [27] and those reactive to activation antigens (antirecipient and the effects of TCV on non-targeted clonal specificities that were not included in the vaccine. ergotypic). [41] The specific importance of anti-TCR regulation was demonstrated by ourselves and others using defined TCR peptides Initial studies typically used one or two dominant T-cell clones to a defined antigenic sequence of MBP. [27] However, given the from MBP-specific T cells to inhibit and treat EAE and number of myelin-reactive specificities that might be present in a MS, [25, [42] [43] [44] and involvement of ergotypic regulation to the activagiven MS patient, later procedures incorporated multiple antigenic tion molecule, CD25 (interleukin [IL]-2R), was demonstrated after peptides, whole purified myelin proteins, or whole myelin in the TCV by Hong et al. [45] antigen cocktail used for selection and expansion of lines and clones to be included in the vaccine (table I) . These strategies 5. Vaccine Preparation broadened the coverage of potentially encephalitogenic T-cell clones reactive to many myelin determinants. With this approach, The basic approach to preparing the TCV is to stimulate periit will be important to verify which of the included determinants pheral blood mononuclear cells (PBMCs) or CSF mononuclear induce significant responses with prevaccination screening, a parcells with antigen, and then expand the cells specific only for the ticular concern when using DR2-binding peptides in DR2-negaselecting protein or peptide until sufficient numbers of cloned tive patients. Yet another strategy was to expand activated CD4+ T cells are available for vaccination.
[46] PBMCs or CSF cells are T cells present in CSF with IL-2, in order to allow the emergence seeded at cell concentrations sufficient to produce positive proliof naturally induced T-cell specificities that reside closer to the feration responses in the presence of the chosen antigen. Wells target organ.
[47] The expanded T cells could then be characterized containing cells that are proliferating (a split well approach is used for response to known myelin antigens, TCR expression, and to assess uptake of 3 H-thymidine) to antigen are expanded in the cytokine profiles. presence of IL-2 and then periodically restimulated with the same antigen into T-cell lines that are then cloned by limiting dilution.
Clinical Outcome Measures These cloned cells are stimulated by phytohemagglutinin (PHA) in the presence of additional autologous antigen-presenting cells
There are now reports from at least seven different early-stage (typically irradiated PBMCs), followed by further IL-2 expanclinical trials using TCV in MS patients, with six additional trials sions. When a sufficient number of cells is recovered, cells are in progress or recently completed but not yet reported (recently activated (with antigen or PHA) and attenuated using radiation reviewed by Hellings et al. [46] ). These drug development trials exposure (6-12 000 rads) to prevent proliferation after injection have been focused largely on treatment variables (i.e. the cell into the patient.
number, dosage and composition of the T-cell vaccine, source of The beauty of the TCV approach is that the methods for myelin-reactive T cells from blood or CSF, patient subtypes), with preparing the cell vaccine are highly refined and generally consisonly the most recent ones being designed to demonstrate definitive tent from laboratory to laboratory. One exception, however, is that proof of the efficacy of the approach in treating MS. However, some studies employ pure T-cell clones, whereas others use shortfrom the published reports, there are many hopeful signs to sugterm T-cell lines that may retain T-cell clonotypes reactive to nongest that, at least, patients with some subtypes of MS are being selected but potentially important host-protective determinants.
helped by the TCV approach. It is possible to determine at each step whether the cells in each
The initial landmark pilot studies conducted in Belgium inresponsive well are specific for the selecting antigen, the composivolved eight MS patients (five with relapsing-remitting [RR]-MS, tion of CD4+ versus CD8+ responder cells, the identity of the TCR two with secondary progressive [SP]-MS, and one with primary BV and AV chains and the actual sequences of the CDR3 that progressive [PP]-MS) who received three subcutaneous injections, define clonality, the degree of expression of activation markers, spaced apart by 2-4 months, of 15 million activated, irradiated the cytokine profile present in cell culture supernatants, and other MBP-specific T-cell clones. [49] The vaccination was well toleratdiscriminatory features of interest. Moreover, the comparison of ed, with no adverse effects other than skin redness at the injection several different clonal populations can determine if a response is site. Remarkably, responses to MBP decreased to background oligoclonal to the peptide antigen of choice. Finally, this sort of levels in all vaccinated patients, concomitant with a reduction in analysis lends itself well to determining whether vaccination the rate of relapses and stabilization of disease scores and brain reduces the frequency of the targeted antigen-specific T cells in the lesions. In three of the vaccinated patients, MBP-reactive T cells Belgium [50] clones specific for MBP (each clone 10 of different clonal origins reappeared after 18-22 months, which MS and one SP-MS patient. All five patients in this pilot trial remained clinically stable or improved based on the EDSS, with was coincident with relapses and increased brain lesions in two no relapses over a 1-year follow-up period. Antimyelin T-cell patients. [54] Later studies determined that the new MBP specificiresponses remained low or were reduced in all patients. These ties could be regulated successfully by additional vaccinations. [55] encouraging preliminary results led to a double-blind, placeboThese studies were followed by an evaluation of TCV effects in controlled trial involving 29 early-stage RR-MS patients (Stinis-49 MS patients from Belgium and 54 patients (28 RR-MS and sen P, personal communication), which has now been completed 26 SP-MS) from the US. [50, 51] These studies confirmed the consis-
but not yet reported (table I) . tent reduction of MBP-specific T cells after TCV and the prolonged time to progression in both RR-MS and SP-MS patients compared with prevaccination rates.
7. Characterization of Vaccine-Reactive T Cells Using bovine myelin-selected T cells with vaccination every 3 months over 2 years, Correale and colleagues [52] in the US Vaccination with at least 10 million whole attenuated T cells followed four SP-MS patients for an additional year for clinical results in the expansion of a second set of T cells specific for both and immunologic changes. Clinically, two vaccinated patients clonotypic and ergotypic determinants. Anticlonotypic T cells remained stable (based on the expanded disability status scale have been shown to consist of both CD4+ and CD8+ T cells, with [EDSS] and ambulation index), one improved, and one fine specificity for hypervariable TCR regions, including both progressed. Immunologically, T cells specific for whole myelin or CDR2 and CDR3 determinants that are probably self presented by selected myelin peptides decreased by 80-90% in all patients after the targeted myelin-reactive clones.
[44] The CD8+ T cells may be 8-15 months of vaccination. This trial was followed by a blinded cytotoxic and/or inhibitory for CD4+ target T cells, thus causing study, conducted at the same location, using bovine myelin-stimudeletion or inhibition of the vaccinating T-cell clones. [56] The lated T cells to vaccinate 80 patients with SP-MS (completed but CD4+ T cells are the major cytokine producers and secrete a not yet reported).
variety of cytokines, including IL-4 and IL-10, that may exert In Israel, Achiron and colleagues [53] vaccinated 20 patients with regulatory effects on the potentially pathogenic Th1 cells selected RR-MS, who were non-responsive to interferon-β, glatiramer for the TCV. [50, 57] Moreover, the regulatory CD4+ subset specific acetate, or intravenous immunoglobulin therapy, using three doses for the vaccinating T cells may include FoxP3+ Treg cells that of ≤60 million irradiated T cells that had been selected against a inhibit the activation of target T cells non-specifically through T-T panel of MBP and MOG peptides. The results of this study showed interactions.
[45, 58, 59] that vaccinated patients had a significant reduction in the annual Given the use of whole cell vaccines comprising activated relapse rate and MRI activity 1 year after the last TCV injection T cells, there may be many potential ergotypic determinants and when compared with the 1-and 2-year pretreatment values. These many anti-ergotypic cell types involved. Both heat-shock proteins promising results spurred additional TCV trials using T cells and the cytokine receptors IL-2R and tumor necrosis factor recepselected with MBP, PLP, and MOG peptides to treat 80 probable tor have been identified as two important ergotypic targets, but MS patients at Sheba Medical Center in Tel Hashomer, Israel conceivably there may be many more such cellular determinants (Lavie G, personal communication). In another phase I/II study, that become immunogenic under TCV conditions. [41] In addition to initiated in Jerusalem, Israel, 30 RR-MS and PR-MS patients were CD4+ and MHC class I-restricted CD8+ cells, HLA-E-restricted enrolled, 20 receiving TCV and 10 receiving placebo (Abulafia-T cells, TCRγδ+ T cells, CD4-CD8 T cells, FoxP3+ Treg cells, and Lapid R et al., unpublished data). TCV was composed of MBP-, natural killer cells have been potentially implicated in recognition MOG-, and PLP-specific T-cell lines. Patients received 30 million and reactivity to ergotypic determinants on activated T cells. [46] In cells, i.e. 10 million of each cell line (see table I for details).
one report by Hong et al., [45] all antivaccine reactivity mediated by Finally, three clinical studies have been carried out using CSF-CD4+ TCRαβ+ T cells was directed against epitopes derived from derived T cells. The initial study using CSF-derived T cells from the CD25 (IL-2R) molecule, implicating ergotopes as major confour progressive MS patients as a vaccine showed that vaccination tributors to the TCV mechanism. It is noteworthy that antibodies was safe and induced short-term immunosuppression.
[48] The to clonotypic or ergotypic determinants have rarely been observed second study by van der Aa et al.
[47] involved TCV with three in TCV-treated MS patients, [50] with the exception of a single injections of 10 million IL-2-expanded CSF cells from four RRreport by Hong et al. [60] 8. Effects on Target and Bystander Cells on enhancing versus inhibitory effects of TCV, it may be necessary to utilize component molecules or epitopes, such as T-cell The major effect of TCV is to delete or downregulate activation receptor determinants, that consistently inhibit autoimmune reof the targeted T cells. The disappearance of T-cell clones used in sponses. the vaccination procedure has been one of the most consistent findings of the various studies. [46] Regulatory properties of non-10. Conclusion CD8+ T cells can be demonstrated in vitro, including TCRreactive CD4+ regulatory T cells, and it is likely that such regulaOverall, study results are indeed impressive and lend direct tion also takes place to some degree in vivo after TCV. [56] The support to the involvement of inflammatory myelin-reactive secretion of regulatory cytokines and the recognition of ergotypic T cells in the MS disease process in some patients. However, the determinants would clearly be expected to have substantial inhibitrends reported in the many pilot studies reviewed here need to be tory effects on bystander T cells that express activation markers validated in double-blind, placebo-controlled trials. These trials but different clonotypic sequences in their TCRs. This bystander are now in progress and will soon reveal whether the current statesuppression may be important in modulating disease, particularly of-the-art in TCV can exert a net positive effect on the course of during the vaccination period and shortly thereafter, but the evi-MS. It is also conceivable that the double-blind trials will show a dence showing the appearance of new specificities of myelinsignificant but not a pronounced effect on the progression of MS. reactive T cells after 1-3 years argues that, at best, regulatory If this should occur, one must then consider that there may be effects of TCV on bystander T cells are temporal. This limited additional destructive processes at work that are relatively unafeffect may be related to the reported poor growth characteristics of fected by this elegant approach to specific regulation of inflammaanti-ergotypic T cells. tion directed at myelin antigens.
Strengths and Weaknesses of the TCV Approach

